Lymphoma - systemic anaplastic large cell lymphoma
The PBS subsidises brentuximab vedotin for eligible patients with systemic anaplastic large cell lymphoma.
Treatment with brentuximab vedotin can be subsidised through the Pharmaceutical Benefits Scheme under section 100 – Efficient funding of chemotherapy of the National Health Act 1953 for patients with CD 30 positive systemic anaplastic large cell lymphoma.
Section 100 arrangements
This item is available to a patient who is attending:
- an approved private hospital
- a public participating hospital, or
- a public hospital
and is either a
- day admitted patient
- non-admitted patient, or
- patient on discharge
This item is not PBS subsidised for in-patients of the hospital. You must include the hospital name and provider number on the authority application form.
Patients must be eligible for the PBS and meet the relevant restriction criteria.
The Schedule of Pharmaceutical Benefits on the PBS website outlines restrictions for prescribing brentuximab vedotin.
Make all initial applications for authority approval to prescribe brentuximab vedotin for the treatment of CD 30 positive systemic anaplastic large cell lymphoma in writing and:
All applications must include a completed:
- authority prescription form(s), and
- Brentuximab vedotin - CD30 positive systemic anaplastic large cell lymphoma Initial PBS authority application Supporting information (PB123)
Treatment must not exceed a lifetime total of 16 cycles.
Applications for continuing brentuximab vedotin treatment of CD 30 positive systemic anaplastic large cell lymphoma can be made by calling the PBS Complex Drugs Programs enquiry line.
For more information contact us on the Complex Drugs enquiry line.
Page last updated: 1 April 2019